Research programme: anti-infectives - Cengent Therapeutics

Drug Profile

Research programme: anti-infectives - Cengent Therapeutics

Alternative Names: ALF inhibitors research programme - Cengent Therapeutics; Zinc metalloprotease inhibitors - Cengent

Latest Information Update: 29 Aug 2007

Price : $50

At a glance

  • Originator Cengent Therapeutics
  • Class Small molecules
  • Mechanism of Action Anthrax toxin inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 29 Aug 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
  • 24 Nov 2003 Preclinical data from a media release have been added to the Bacterial Infections pharmacodynamics section
  • 27 May 2003 Cengent Therapeutics' ALF inhibitors are available for licensing and further development (http://www.cengent.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top